Outros sites Medialivre
Caldeirão da Bolsa

GRIFOLS (IBEX-35)

Espaço dedicado a todo o tipo de troca de impressões sobre os mercados financeiros e ao que possa condicionar o desempenho dos mesmos.

por Titleist » 17/7/2012 23:28

Grafico atualizado - variação anual de 72.31%
Anexos
Grifolis.PNG
Grifolis.PNG (30.42 KiB) Visualizado 14376 vezes
"O $$$ foi feito para se gastar 8-), não para se perder :( ..."
Avatar do Utilizador
 
Mensagens: 726
Registado: 5/12/2006 16:44
Localização: Estoril

por Titleist » 17/7/2012 23:22

Grifols SA : Araclon Biotech has identified a new blood protein with diagnostic value for Alzheimer’s disease07/17/2012 | 08:35am US/Eastern

•The Spanish biotech firm, in which Grifols has a majority shareholding, has presented the first results at the Alzheimer's Association International Conference in Vancouver (Canada)
Barcelona, July 17, 2012: Studies performed by Araclon Biotech, the Spanish biotech firm in which Grifols has a majority shareholding, have made it possible to quantify the protein A
"O $$$ foi feito para se gastar 8-), não para se perder :( ..."
Avatar do Utilizador
 
Mensagens: 726
Registado: 5/12/2006 16:44
Localização: Estoril

por Titleist » 12/7/2012 19:15

grafico atualizado
Anexos
GRIFOLS.PNG
GRIFOLS.PNG (35.51 KiB) Visualizado 14412 vezes
"O $$$ foi feito para se gastar 8-), não para se perder :( ..."
Avatar do Utilizador
 
Mensagens: 726
Registado: 5/12/2006 16:44
Localização: Estoril

por Titleist » 12/7/2012 19:12

"O $$$ foi feito para se gastar 8-), não para se perder :( ..."
Avatar do Utilizador
 
Mensagens: 726
Registado: 5/12/2006 16:44
Localização: Estoril

por Titleist » 11/7/2012 14:16

Hoje ja cotou nos 22.185
Anexos
GRIFOLS.PNG
GRIFOLS.PNG (35.34 KiB) Visualizado 14476 vezes
"O $$$ foi feito para se gastar 8-), não para se perder :( ..."
Avatar do Utilizador
 
Mensagens: 726
Registado: 5/12/2006 16:44
Localização: Estoril

por Titleist » 11/7/2012 14:11

07/09/2012 | 11:24am US/Eastern

Moody's upgrades Grifols' Credit Rating and changes Outlook to Positive Grifols' senior secured debt upgraded one notch to Ba2, while unsecured debt reaches B2 and its global corporate rating is upgraded to Ba3 Barcelona, July 9, 2012.- Grifols (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), The world's third-largest producer of plasma-derived biological medicines, has achieved a credit rating upgrade from Moody's in its latest review. Grifols' Global Corporate rating has been upgraded to Ba3, while its senior secured debt reaches Ba2 and its senior unsecured debt reaches B2. The outlook on all the ratings is positive.
According to Moody's, the rating upgrade reflects the significant progress made by the Company in achieving planned synergies from the acquisition of Talecris Biotherapeutics Holding Corp. Prepayments of around USD 240 million in February 2012 as part of the refinancing of its senior debt, which further reduced financing costs and strong double digit organic growth in both sales and EBITDA as reported in first quarter 2012 have allowed to reduce gross leverage and improved cash interest cover. The conservative financial policy of the company, as evidenced by the decision not to payout a dividend in 2012 is also supporting the upgrade.
The positive outlook incorporates Moody's assumption that Grifols will continue to improve its leverage, driven by both further improving EBITDA and continued reduction in gross indebtedness. It also incorporates the assumption of the existence of considerable synergies potential to be realized.
"O $$$ foi feito para se gastar 8-), não para se perder :( ..."
Avatar do Utilizador
 
Mensagens: 726
Registado: 5/12/2006 16:44
Localização: Estoril

por Titleist » 3/7/2012 19:26

Poderá justificar-se em parte por isto:

... Grifols (MCE:GRF, MCE:GRF.P and NASDAQ: GRFS), the world's third largest plasma product manufacturer and a pioneer in the research and development of therapeutic alternatives designed to contribute to both scientific and social development, has acquired 51% of the equity of Zaragoza-based company Araclon Biotech, ensuring the viability of its projects and the future of the company.

Araclon Biotech was created in 2004 as a spin-off from the University of Zaragoza, and specializes in the research and development of therapies and diagnostic methods for neurodegenerative diseases, although it is currently focusing on Alzheimer's disease (AD), a condition for which there is no cure and of which there are around 350,000 to 380,000 sufferers in Spain[1] and over 25 million in the world[2].

Grifols completed the operation by acquiring a stake in the company through Gri-Cel S.A., an investment vehicle created in 2010 to promote the group's participation in fields of medicine which lie outside the scope of its main activities, such as advanced therapies.

Following the purchase, Grifols has become Araclon Biotech's largest shareholder, with a 51% holding, while other founding partners retain 49% of the capital.

Source: PR Newswire (http://s.tt/1bEd3)
"O $$$ foi feito para se gastar 8-), não para se perder :( ..."
Avatar do Utilizador
 
Mensagens: 726
Registado: 5/12/2006 16:44
Localização: Estoril

por richardj » 3/7/2012 19:14

o que motivou o brutal aumento de vendas dos últimos 2 anos?
Avatar do Utilizador
 
Mensagens: 2699
Registado: 25/4/2011 22:36
Localização: Drama City

por Titleist » 3/7/2012 19:10

análise técnica - tendencia
Anexos
GRIFOLS technical analysis.PNG
GRIFOLS technical analysis.PNG (12.43 KiB) Visualizado 14565 vezes
"O $$$ foi feito para se gastar 8-), não para se perder :( ..."
Avatar do Utilizador
 
Mensagens: 726
Registado: 5/12/2006 16:44
Localização: Estoril

por Titleist » 3/7/2012 19:08

Gráfico
Anexos
GRIFOLS.PNG
GRIFOLS.PNG (88.45 KiB) Visualizado 14593 vezes
"O $$$ foi feito para se gastar 8-), não para se perder :( ..."
Avatar do Utilizador
 
Mensagens: 726
Registado: 5/12/2006 16:44
Localização: Estoril

GRIFOLS (IBEX-35)

por Titleist » 3/7/2012 19:06

Dados da empresa
Grifols specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows:
- products derived from plasma (85.5%): products for use by the pharmaceutical and biotechnology industries;
- diagnostic machines and reagents (6.5%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;
- hospital products (5.3%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;
- other (2.9%): primarily intermediate biological products and subcontracted manufacturing services.
Net sales break down geographically as follows: Spain (12.9%), Europe (16.5%), the United States (54.3%) and other (16.3%).

Shareolders
- Capital Research and Management Company 10,02%
- Deria 8,77%
- Thorthol Holdings 7,06%
- Scranton Enterprises 7,58%
- Mister Grifols Lucas Victor 6,15%
- American Funds Insurance Series Growth Fund 3,00%
- Fidelity International Limited 1,13%
"O $$$ foi feito para se gastar 8-), não para se perder :( ..."
Avatar do Utilizador
 
Mensagens: 726
Registado: 5/12/2006 16:44
Localização: Estoril

Anterior

Quem está ligado:
Utilizadores a ver este Fórum: bento.jp13, Bing [Bot], Google [Bot], niceboy, papamericano e 162 visitantes